HGH PEPTIDES

GHRP 6

What represents today a family of peptidyl GH secretagogues with broad cytoprotective properties, came to light by the American endocrinologist Cyril Bowers, who observed that chemical analogs of enkephalin amide showed GH releasing activity upon their incorporation to pituitary cultures. GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) appeared as the first in line synthetic peptide which specifically elicited GH dosage-related release in vitro and in vivo. Afterwards a heptapeptide, GHRP-1, and two other hexapeptides, GHRP-2 and Hexarelin, were synthesized and addressed to basic and sporadic clinical studies. Although at the beginning GHRP seemed to linger as an instrumental tool within the endocrinologist armamentarium, ulterior findings unraveled unexpected pharmacological properties. GHRP family members began to shine by their ability to prevent cardiac cells demise as to induce the restoration of critical cardiac functions upon ischemia/reperfusion episodes. A novel generation of promising cardioprotective agents had started to rise and to set a bridge between endocrinology and cardiology.